Brief: Peptidream - Subsidiary PDR Pharma Signs Agreement With Eli Lilly To Jointly Develop Alzheimer's Diagnostic Agent Flortaucipir In Japan
24/11/2022 03:07
Nov 24 (Reuters) - PeptiDream Inc 4587.T :
* SUBSIDIARY PDR PHARMA SIGNS AGREEMENT WITH ELI LILLY TO
JOINTLY
DEVELOP ALZHEIMER'S DIAGNOSTIC AGENT FLORTAUCIPIR IN JAPAN
Further company coverage: 4587.T
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner